Large cell differentiation of metastatic prostate cancer after androgen deprivation therapy

被引：1
|
作者：
Patel, Rutveej [1 ]
Faiena, Izak [1 ]
Geltzeiler, Jules [2 ]
机构：
[1] Rutgers Robert Wood Johnson Med Sch, Div Urol, New Brunswick, NJ USA
[2] Jersey Shore Univ, Med Ctr, Div Urol, Neptune, NJ USA
来源：
CANADIAN JOURNAL OF UROLOGY | 2015年 / 22卷 / 02期
关键词：
large cell neuroendocrine tumor; prostate cancer; hormone refractory prostate cancer; neuroendocrine differentiation; NEUROENDOCRINE DIFFERENTIATION;
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
We present a case of a 75-year-old male with a history of high risk prostate cancer who underwent androgen deprivation therapy and palliative radiation treatments for his disease. Subsequently, he presented with gross hematuria and severe lower urinary tract symptoms. A palliative transurethral resection of the prostate (TURP) at that time, demonstrated large cell differentiated neuroendocrine carcinoma with metastasis to the lung. We review the limited literature on this rare form of disease and present current treatment strategies.
引用
收藏
页码：7752 / 7754
页数：3
相关论文
共 50 条
  • [21] Secondary Cancer after Androgen Deprivation Therapy in Prostate Cancer: A Nationwide Study
    Kim, Jae Heon
    Bae, Gi Hwan
    Jung, Jaehun
    Il Noh, Tae
    WORLD JOURNAL OF MENS HEALTH, 2025, 43 (01): : 123 - 133
  • [22] Decreased testosterone recovery after androgen deprivation therapy for prostate cancer
    Long, Margaret E.
    Vitale, Andrew M.
    Mott, Sarah L.
    Tracy, Chad
    Garje, Rohan
    Zakharia, Yousef
    Brown, James A.
    CANADIAN JOURNAL OF UROLOGY, 2021, 28 (04) : 10738 - 10742
  • [23] Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer
    Sathianathen, Niranjan J.
    Oestreich, Makinna C.
    Brown, Sarah Jane
    Gupta, Shilpa
    Konety, Badrinath R.
    Dahm, Philipp
    Kunath, Frank
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (12):
  • [24] Androgen Deprivation Therapy and the Risk of Dementia after Treatment for Prostate Cancer
    Lonergan, Peter E.
    Washington, Samuel L., III
    Cowan, Janet E.
    Zhao, Shoujun
    Broering, Jeanette M.
    Cooperberg, Matthew R.
    Carroll, Peter R.
    JOURNAL OF UROLOGY, 2022, 207 (04): : 832 - 840
  • [25] Prolonged hypogonadism after cessation of androgen deprivation therapy for prostate cancer
    Rodriguez-Rubio Cortadellas, Federico I.
    Jimenez Romero, Miguel E.
    Gonzalez Moreno, Delfin
    Novalbos Ruiz, Jose P.
    Garrido Insua, Sofia
    ACTAS UROLOGICAS ESPANOLAS, 2009, 33 (07): : 747 - 754
  • [26] miRNAs and androgen deprivation therapy for prostate cancer
    Konoshenko, Maria Yu
    Bryzgunova, Olga E.
    Laktionov, Pavel P.
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2021, 1876 (02):
  • [27] Prostate cancer, insulin, and androgen deprivation therapy
    Stattin, P
    Kaaks, R
    BRITISH JOURNAL OF CANCER, 2003, 89 (09) : 1814 - 1815
  • [28] Androgen Deprivation Therapy and Prostate Cancer Duration
    Williams, Scott G.
    Pickles, Tom
    Buyyounouski, Mark K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) : E228 - E228
  • [29] An update on androgen deprivation therapy for prostate cancer
    Sharifi, Nima
    Gulley, James L.
    Dahut, William L.
    ENDOCRINE-RELATED CANCER, 2010, 17 (04) : R305 - R315
  • [30] Intermittent androgen deprivation therapy for prostate cancer
    Rashid, MH
    Chaudhary, UB
    ONCOLOGIST, 2004, 9 (03): : 295 - 301
12345